Annual report pursuant to Section 13 and 15(d)

Stock-Based Compensation (Tables)

v3.23.1
Stock-Based Compensation (Tables)
12 Months Ended
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of shares available for future grant
As of December 31, 2022, the shares available for future grant under the 2014 Amended and Restated Plan are as follows:
Shares Available for Grant
Available as of December 31, 2021 14,132,929 
Share pool increase 35,731,891 
Forfeited 3,810,345 
Cancelled 1,232,218 
Granted (12,632,626)
Available as of December 31, 2022 42,274,757 
Schedule of summary of stock option activity
The following is a summary of option activities under the Company’s 2014 Amended and Restated Plan for the year ended December 31, 2022:
Number of
Shares
Weighted
Average
Exercise Price
Weighted
Average Remaining
Contractual
Term (Years)
Aggregate
Intrinsic
Value*
Outstanding, December 31, 2021 35,405,000  $ 0.07  9.08 $ 134,750 
Granted (1)
12,632,626  0.49 
Forfeited (1,232,218) 0.47 
Cancelled (3,810,346) 0.07 
Outstanding, December 31, 2022 42,995,062  $ 0.18  7.14 $  
Exercisable, December 31, 2022 25,441,484  $ 0.08  7.8 $  
Vested and expected to vest, December 31, 2022 42,995,062  $ 0.18  7.14 $  
*The aggregate intrinsic value is the sum of the amounts by which the quoted market price of the Company’s stock exceeded the exercise price of the stock options at December 31, 2022 for those stock options for which the quoted market price was in excess of the exercise price ("in-the-money options").
(1) Includes 8,282,626 rollover options issued under the 2014 Plan related to the Acquisition. Upon the closing of the Acquisition, the entire fair value of the EHT rollover options was allocated to the purchase consideration. As a result the assumptions below exclude the EHT rollover options (See Note 3)
Schedule of fair value assumptions of stock option granted
The fair value of each stock option grant was estimated on the date of grant using the Black-Scholes option-pricing model under the following assumptions:
Year Ended December 31,
2022 2021
Dividend yield 0.00  % 0.00  %
Risk-free interest rate
2.89-3.60%
0.01-1.11%
Expected term (years)
5.00-6.08
5.27-6.13
Volatility
126.27-132.58%
119.10-138.00%
Schedule of RSA activity The following is a summary of restricted stock unit activity during the year ended December 31, 2022:
Number of
Shares
Weighted Average Grant Date Fair Value
Unvested, December 31, 2021 4,000,000  $ 0.06 
Granted —  — 
Released (1,333,333) 0.06 
Unvested, December 31, 2022 2,666,667  $ 0.06 
The following is a summary of restricted stock activity outside of the 2014 Amended and Restated Plan during the year ended December 31, 2022:
Number of Shares Weighted Average Grant Date Fair Value
Unvested, December 31, 2021 150,000  $ 0.13 
Granted —  — 
Released (150,000) 0.13 
*Unvested, December 31, 2022   $  
Schedule of Stock-Based compensation Expense The Company recognized stock-based compensation expense, including compensation expense for warrants with vesting provisions issued to a service provider (Note 6), and the RSUs discussed above, in its Consolidated Statements of Operations as follows:
Year Ended
December 31,
2022 2021
Research and development $ 77,965  $ 59,653 
General and administrative 530,234  809,553 
$ 608,199  $ 869,206